HRP20100675T1 - Derivati pirazola kao modulatori protein kinaze - Google Patents

Derivati pirazola kao modulatori protein kinaze Download PDF

Info

Publication number
HRP20100675T1
HRP20100675T1 HR20100675T HRP20100675T HRP20100675T1 HR P20100675 T1 HRP20100675 T1 HR P20100675T1 HR 20100675 T HR20100675 T HR 20100675T HR P20100675 T HRP20100675 T HR P20100675T HR P20100675 T1 HRP20100675 T1 HR P20100675T1
Authority
HR
Croatia
Prior art keywords
phenyl
pyrazol
group
chloro
compound according
Prior art date
Application number
HR20100675T
Other languages
English (en)
Inventor
Berdini Valerio
Saxty Gordon
Leendert Verdonk Marinus
John Woodhead Steven
Graham Wyatt Paul
George Boyle Robert
Fiona Sore Hannah
Winter Walker David
Collins Ian
Downham Robert
Arthur Ellis Carr Robin
Original Assignee
Astex Therapeutics Limited
Cancer Research Technology Limited
The Institute Of Cancer Research: Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329617A external-priority patent/GB0329617D0/en
Application filed by Astex Therapeutics Limited, Cancer Research Technology Limited, The Institute Of Cancer Research: Royal Cancer Hospital filed Critical Astex Therapeutics Limited
Publication of HRP20100675T1 publication Critical patent/HRP20100675T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Spoj formule (I): (I) ili njegova sol, solvat, tautomer ili N-oksid; naznacen time sto je A zasicena ugljikovodicna vezna skupina koja sadrzi 1 do 7 atoma ugljika, ta vezna skupina ima najvecu duljinu lanca od 5 atoma koji se pruzaju izmedu R1 i NR2R3 i najvecu duljinu lanca od 4 atoma koji se pruzaju izmedu E i NR2R3, gdje jedan od atoma ugljika u veznoj skupini moze po izboru biti zamijenjen atomom kisika ili dusika; i gdje atomi ugljika vezne skupine A mogu po izboru imati jedan ili vise supstituenata izabranih izmedu okso, fluora i hidroksi, uz uvjet da se hidroksilna skupina, kada je prisutna, ne nalazi na α atomu ugljika u odnosu na NR2R3 skupinu i uz uvjet da se okso skupina, kada je prisutna, nalazi na α atomu ugljika u odnosu na NR2R3 skupinu; E je monociklicka ili biciklicka karbociklicka ili heterociklicka skupina pri cemu E nije supstituiran ili ima do 4 supstituenta R8 izabrana izmedu hidroksi, okso (kada E nije aromatski), klor, brom, trifluorometil, cijano, C1-4 hidrokarbiloksi i C1-4 hidrokarbil po izboru supstituiran s C1-2 alkoksi ili hidroksil; R1 je arilna ili heteroarilna skupina koja nije supstituirana ili ima jedan ili vise supstituenata izabranih izmedu hidroksi; C1-4 aciloksi; fluor; klor; brom; trifluorometil; cijano; CONH2; nitro; C1-4 hidrokarbiloksi i C1-4 hidrokarbil od kojih svaki moze po izboru biti supstituiran s C1-2 alkoksi, karboksi ili hidroksi; C1-4 acilamino; benzoilamino; pirolidinokarbonil; piperidinokarbonil; morfolinokarbonil; piperazinokarbonil; petero- i sesteroclane heteroarilne i heteroariloksi skupine sadrze jedan ili dva heteroatoma izabrana izmedu N, O i S; fenil; fenil C1-4 alkil; fenil-C1-4 alkoksi; heteroaril-C1-4 alkil; heteroaril-C1-4 alkoksi i fenoksi, gdje su skupine heteroaril, heteroariloksi, fenil, fenil C1-4 alkil, fenil-C1-4 alkoksi, heteroaril C1-4 alkil, heteroaril-C1-4 alkoksi i fenoksi svaka po izboru supstituirane s 1, 2 ili 3 supstituenta izabrana izmedu C1-2 aciloksi, fluor, klor, brom, trifluorometil, cijano, CONH2, C1-2 hidrokarbiloksi i C1-2 hidrokarbil od kojih je svaki po izboru supstituiran sa metoksi ili hidroksil; R2 i R3 su nezavisno jedan od drugog izabrani izmedu vodika, C1-4 hidrokarbil i C1-4 acil gdje hidrokarbilni i acilni dijelovi mogu po izboru biti supstituirani jednim ili s vise supstituenta izabrana izmedu fluor, hidroksi, amino, metilamino, dimetilamino i metoksi; ili R2 i R3 zajedno s atomom dusika, na koji su vezani, tvore ciklicku skupinu izabranu izmedu imidazolske skupine i zasicene monociklicke heterociklicke skupine s 4-7 clanova prstena i koja po izboru sadrzi drugi heteroatomni clan prstena izabran izmedu O i N; ili jedan od R2 i R3 zajedno s atomom dusika, na koji su vezani, i s jednim ili vise atoma iz vezne skupine A tvore zasicenu monociklicku heterociklicku skupinu s 4-7 clanova prstena i koja po izboru sadrzi drugi heteroatomni clan prstena izabran izmedu O i N; ili NR2R3 i atom ugljika vezne skupine A na koji je spojen, zajedno tvor

Claims (54)

1. Spoj formule (I): [image] (I) ili njegova sol, solvat, tautomer ili N-oksid; naznačen time što je A zasićena ugljikovodična vezna skupina koja sadrži 1 do 7 atoma ugljika, ta vezna skupina ima najveću duljinu lanca od 5 atoma koji se pružaju između R1 i NR2R3 i najveću duljinu lanca od 4 atoma koji se pružaju između E i NR2R3, gdje jedan od atoma ugljika u veznoj skupini može po izboru biti zamijenjen atomom kisika ili dušika; i gdje atomi ugljika vezne skupine A mogu po izboru imati jedan ili više supstituenata izabranih između okso, fluora i hidroksi, uz uvjet da se hidroksilna skupina, kada je prisutna, ne nalazi na α atomu ugljika u odnosu na NR2R3 skupinu i uz uvjet da se okso skupina, kada je prisutna, nalazi na α atomu ugljika u odnosu na NR2R3 skupinu; E je monociklička ili biciklička karbociklička ili heterociklička skupina pri čemu E nije supstituiran ili ima do 4 supstituenta R8 izabrana između hidroksi, okso (kada E nije aromatski), klor, brom, trifluorometil, cijano, C1-4 hidrokarbiloksi i C1-4 hidrokarbil po izboru supstituiran s C1-2 alkoksi ili hidroksil; R1 je arilna ili heteroarilna skupina koja nije supstituirana ili ima jedan ili više supstituenata izabranih između hidroksi; C1-4 aciloksi; fluor; klor; brom; trifluorometil; cijano; CONH2; nitro; C1-4 hidrokarbiloksi i C1-4 hidrokarbil od kojih svaki može po izboru biti supstituiran s C1-2 alkoksi, karboksi ili hidroksi; C1-4 acilamino; benzoilamino; pirolidinokarbonil; piperidinokarbonil; morfolinokarbonil; piperazinokarbonil; petero- i šesteročlane heteroarilne i heteroariloksi skupine sadrže jedan ili dva heteroatoma izabrana između N, O i S; fenil; fenilC1-4 alkil; fenil-C1-4 alkoksi; heteroaril-C1-4 alkil; heteroaril-C1-4 alkoksi i fenoksi, gdje su skupine heteroaril, heteroariloksi, fenil, fenilC1-4 alkil, fenil-C1-4 alkoksi, heteroarilC1-4 alkil, heteroaril-C1-4 alkoksi i fenoksi svaka po izboru supstituirane s 1, 2 ili 3 supstituenta izabrana između C1-2 aciloksi, fluor, klor, brom, trifluorometil, cijano, CONH2, C1-2 hidrokarbiloksi i C1-2 hidrokarbil od kojih je svaki po izboru supstituiran sa metoksi ili hidroksil; R2 i R3 su nezavisno jedan od drugog izabrani između vodika, C1-4 hidrokarbil i C1-4 acil gdje hidrokarbilni i acilni dijelovi mogu po izboru biti supstituirani jednim ili s više supstituenta izabrana između fluor, hidroksi, amino, metilamino, dimetilamino i metoksi; ili R2 i R3 zajedno s atomom dušika, na koji su vezani, tvore cikličku skupinu izabranu između imidazolske skupine i zasićene monocikličke heterocikličke skupine s 4-7 članova prstena i koja po izboru sadrži drugi heteroatomni član prstena izabran između O i N; ili jedan od R2 i R3 zajedno s atomom dušika, na koji su vezani, i s jednim ili više atoma iz vezne skupine A tvore zasićenu monocikličku heterocikličku skupinu s 4-7 članova prstena i koja po izboru sadrži drugi heteroatomni član prstena izabran između O i N; ili NR2R3 i atom ugljika vezne skupine A na koji je spojen, zajedno tvore cijano skupinu; R4 je izabran između vodika, halogena, C1-5 zasićenog hidrokarbila, C1-5 zasićenog hidrokarbiloksi, cijano, i CF3; i R5 je izabran između vodika, halogena, C1-5 zasićenog hidrokarbila, C1-5 zasićenog hidrokarbiloksi, cijano, CONH2, CONHR9, CF3, NH2, NHCOR9 ili NHCONHR9; R9 je skupina R9a ili (CH2)R9a, pri čemu je R9a monociklička ili biciklička skupina koja može biti karbociklička ili heterociklička; karbociklička skupina ili heterociklička skupina R9a je po izboru supstituirana jednim ili više supstituenata izabrana između halogena, hidroksi, trifluorometil, cijano, nitro, karboksi, amino, mono- ili di-C1-4 hidrokarbilamino; skupina Ra-Rb gdje je Ra veza, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc ili NRcSO2; i Rb je izabran između vodika, heterocikličke skupine s 3 do 12 članova prstena, i C1-8 hidrokarbilne skupine po izboru supstituirane jednim ili više supstituenta izabrana između hidroksi, okso, halogen, cijano, nitro, karboksi, amino, mono- ili di-C14 hidrokarbilamino, karbocikličke i heterocikličke skupine imaju od 3 do 12 članova prstena i gdje jedan ili više atoma ugljika C1-8 hidrokarbilne skupine mogu po izboru biti zamijenjeni s O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 ili X1C(X2)X1; Rc je izabran između vodika i C1-4 hidrokarbila; i X1 je O, S ili NRc i X2je =O, =S ili =NRc.
2. Spoj prema zahtjevu 1 formule (Ia): [image] (Ia) ili njegova sol, solvat, tautomer ili N-oksid; naznačen time što je A zasićena ugljikovodična vezna skupina koja sadrži 1 do 7 atoma ugljika, ta vezna skupina ima najveću duljinu lanca od 5 atoma koji se pružaju između R1 i NR2R3 i najveću duljinu lanca od 4 atoma koji se pružaju između E i NR2R3, gdje jedan od atoma ugljika u veznoj skupini može po izboru biti zamijenjen atomom kisika ili dušika; i gdje atomi ugljika vezne skupine A mogu po izboru imati jedan ili više supstituenata izabranih između okso, fluora i hidroksi, uz uvjet da se hidroksilna skupina, kada je prisutna, ne nalazi na α atomu ugljika u odnosu na NR2R3 skupinu i uz uvjet da se okso skupina, kada je prisutna, nalazi na α atomu ugljika u odnosu na NR2R3 skupinu; E je monociklička ili biciklička karbociklička ili heterociklička skupina pri čemu E nije supstituiran ili ima do 4 supstituenta R8 kako je definirano u zahtjevu 1; R1 je aril ili heteroarilna skupina koja nije supstituirana ili je supstituirana kako je definirano u zahtjevu 1 R2 i R3 su nezavisno jedan od drugog izabrani između vodika, C1-4 hidrokarbil i C1-4 acil; ili R2 i R3 zajedno s atomom dušika, na koji su vezani, tvore zasićenu monocikličku heterocikličku skupinu s 4-7 članova prstena i koja po izboru sadrži drugi heteroatomni član prstena izabran između O i N; ili jedan od R2 i R3 zajedno s atomom dušika, na koji su vezani, i s jednim ili više atoma iz vezne skupine A tvore zasićenu monocikličku heterocikličku skupinu s 4-7 članova prstena i koja po izboru sadrži drugi heteroatomni član prstena izabran između O i N; ili NR2R3 i atom ugljika vezne skupine A na koji je spojen, zajedno tvore cijano skupinu; R4 je izabran između vodika, halogena, C1-5 zasićenog hidrokarbila, cijano i CF3; i R5 je izabran između vodika, halogena, C1-5 zasićenog hidrokarbila, cijano, CONH2, CONHR9,CF3, NH2, NHCOR9 ili NHCONHR9; R9 je fenil ili benzil od kojih svaki po izboru može biti supstituiran jednim ili više supstituenta izabrana između halogena, hidroksi, trifluorometil, cijano, nitro, karboksi, amino, mono- ili di-C1-4 hidrokarbilamino; skupina Ra-Rb gdje je Ra veza, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc ili NRcSO2; i Rb je izabran između vodika, heterocikličke skupine s 3 do 12 članova prstena, i C1-8 hidrokarbilne skupine po izboru supstituirane jednim ili više supstituenta izabrana između hidroksi, okso, halogen, cijano, nitro, karboksi, amino, mono- ili di-C14 hidrokarbilamino, karbocikličke i heterocikličke skupine imaju od 3 do 12 članova prstena i gdje jedan ili više atoma ugljika C1-8 hidrokarbilne skupine mogu po izboru biti zamijenjeni s O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 ili X1C(X2)X1; Rc je izabran između vodika i C1-4 hidrokarbila; i X1 je O, S ili NRc i X2 je =O, =S ili =NRc. Spoj prema zahtjevu 1 ili 2, naznačen time što je A zasićena ugljikovodična vezna skupina koja sadrži 1 do 7 atoma ugljika, ta vezna skupina ima najveću duljinu lanca od 5 atoma koji se pružaju između R1 i NR2R3 i najveću duljinu lanca od 4 atoma koji se pružaju između E i NR2R3, gdje jedan od atoma ugljika u veznoj skupini može po izboru biti zamijenjen atomom kisika ili dušika; i gdje atomi ugljika vezne skupine A mogu po izboru imati jedan ili više supstituenata izabranih između fluora i hidroksi, uz uvjet da se hidroksilna skupina, kada je prisutna, ne nalazi na α atomu ugljika u odnosu na NR2R3; i R5 je izabran između vodika, halogena, C1-5 zasićenog hidrokarbila, cijano, CONH2, CF3, NH2, NHCOR9 i NHCONHR9.
3. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time što vezna skupina A ima najveću duljinu lanca od 3 atoma koji se pružaju između R1 i NR2R3.
4. Spoj prema zahtjevu 4, naznačen time što vezna skupina A ima najveću duljinu lanca od 2 atoma koji se pružaju između R1 i NR2R3.
5. Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time što vezna skupina A ima najveću duljinu lanca od 3 atoma koji se pružaju između E i NR2R3.
6. Spoj prema zahtjevu 6, naznačen time što vezna skupina A ima duljinu lanca od 2 ili 3 atoma koji se pružaju između R1 i NR2R3 i duljinu lanca od 2 ili 3 atoma koji se pružaju između E i NR2R3.
7. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što je atom vezne skupine koji je povezan izravno na skupinu E atom ugljika i vezna skupina A ima u potpunosti ugljični kostur.
8. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time što je dio R1-A-NR2R3 spoja predstavljen formulom R1(G)k-(CH2)m-W-Ob-(CH2)n-(CR6R7)p-NR2R3 gdje G je NH, NMe ili O; W je spojen na skupinu E i izabran je između (CH2)j-CR20, (CH2)j-N i (NH)j-CH; b je 0 ili 1, j je 0 ili 1, k je 0 ili 1, m je 0 ili 1, n je 0, 1, 2, ili 3 i p su 0 ili 1; zbroj b i k je 0 ili 1; zbroj j, k, m, n i p ne prelazi 4; R6 i R7 su isti ili različiti i izabrani su između metil i etil, ili CR6R7 tvori ciklopropil; i R20 je izabran između vodika, metila, hidroksi i fluora.
9. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time što je dio R1-A-NR2R3 predstavljen formulom R1(G)k-(CH2)m-X-(CH2)n-(CR6R7)p-NR2R3 gdje G je NH, NMe ili O; X je spojen na skupinu E i izabran između (CH2)j-CH, (CH2)j-N i (NH)j-CH; j je 0 ili 1, k je 0 ili 1, m je 0 ili 1, n je 0, 1, 2, ili 3 i p je 0 ili 1, i zbroj j, k, m, n i p ne prelazi 4; i R6 i R7 su isti ili različiti i izabrani su između metil i etil, ili CR6R7 tvori ciklopropil.
10. Spoj prema zahtjevu 10, naznačen time što (i) k je 0, m je 0 ili 1, n je 0, 1, 2 ili 3 i p je 0; ili (ii) k je 0, m je 0 ili 1, n je 0, 1 ili 2 i p je 1.
11. Spoj prema zahtjevu 10, naznačen time što (i) X je (CH2)j-CH, k je 1, m je 0, n je 0, 1,2 ili 3 i p je 0; ili (ii) X je (CH2)j-CH, k je 1, m je 0, n je 0, 1 ili 2 i p je 1.
12. Spoj prema zahtjevu 10 ili 12, naznačen time što (i) j je 0; ili (ii) j je 1; ili (iii) CR6R7 je C(CH3)2.
13. Spoj prema zahtjevu 10, naznačen time što je dio R1-A-NR2R3 spoja predstavljen formulom R1X-(CH2)n-NR2R3 gdje je X spojen na skupinu E i to je skupina CH, i n je 2.
14. Spoj prema zahtjevu 1 ili 2, naznačen time što je R1-A(E)-NR2R3 izabran između skupina A1 do A11 u nastavku: [image]
15. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što je E monociklička skupina.
16. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što je E arilna ili heteroarilna skupina od kojih je svaka nesupstituirana ili supstituirana sa do 4 supstituenta R8 kako je definirano u zahtjevu 1.
17. Spoj prema zahtjevu 17, naznačen time što je izabran između po izboru supstituiranog fenila, tiofena, furana, pirimidina i piridina, od kojih je svaki nesupstituiran ili supstituiran sa do 4 supstituenta R8 kako je definirano u zahtjevu 1.
18. Spoj prema zahtjevu 18, naznačen time što je E fenil koji nije supstituiran ili može biti supstituiran sa do 4 supstituenta R8 kako je definirano u zahtjevu 1.
19. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što su skupina A i pirazol spojeni na skupinu E u meta ili para položaju; tj. A i pirazol nisu spojeni na susjedne članove prstena skupine.
20. Spoj prema zahtjevu 20, naznačen time što je E izabran između 1,4-fenilen, 1,3-fenilen, 2,5-piridilen i 2,4-piridilen, 1,4-piperazinil, i 1,4-piperazonil, od koji je svaki nesupstituiran ili supstituirana sa do 4 supstituenta R8 kako je definirano u zahtjevu 1.
21. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što E ima 0-3 supstituenta.
22. Spoj prema zahtjevu 22, naznačen time što E ima 0-2 supstituenta.
23. Spoj prema zahtjevu 23, naznačen time što E ima 0 ili 1 supstituent.
24. Spoj prema zahtjevu 24, naznačen time što E nije supstituiran.
25. Spoj prema zahtjevu 19, naznačen time što ima formulu (II): [image] (II) pri čemu je skupina A spojena u meta ili para položaju prstena benzena i q je 0-4.
26. Spoj prema zahtjevu 26, naznačen time što q je 0, 1 ili 2
27. Spoj prema zahtjevu 27, naznačen time što q je 0 ili 1.
28. Spoj prema zahtjevu 28, naznačen time što q je 0.
29. Spoj prema zahtjevu 19, naznačen time što ima formulu (III): [image] (III) gdje je A’ ostatak skupine A i R1 do R5 su kako je defnirano u bilo kojem od prethodnih zahtjeva.
30. Spoj prema zahtjevu 19, naznačen time što ima formulu (IV): [image] (IV) gdje z je 0, 1 ili 2, R20 je izabran između vodika, metila, hidroksi i fluora, uz uvjet da kada je z jednako 0, R20 nije hidroksi.
31. Spoj prema zahtjevu 19, naznačen time što ima formulu (V): [image] (V) gdje je R3 izabran između vodika i C1-4 hidrokarbila.
32. Spoj prema zahtjevu 32, naznačen time što R3 je vodik.
33. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što je R1 izabran između fenil, naftil, tienil, furan, pirimidin i piridin, od kojih svaki može po izboru biti supstituiran kako je definirano u zahtjevu 1.
34. Spoj prema zahtjevu 26, naznačen time što je R1 fenil.
35. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što R1 nije supstituiran ili je supstituiran sa do 5 supstituenta izabrana između hidroksi, C1-4 aciloksi, fluor, klor, brom, trifluorometil, cijano, C1-4 hidrokarbiloksi i C1-4 hidrokarbil po izboru supstituiran s C1-2 alkoksi ili hidroksi.
36. Spoj prema zahtjevu 36, naznačen time što skupina R1 ima jedan ili dva supstituenta izabrana između fluor, klor, trifluorometil, metil i metoksi.
37. Spoj prema zahtjevu 37, naznačen time što je R1 mono-klorofenil ili diklorofenil skupina.
38. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što je R4 izabran između vodika i metila.
39. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što je R5 izabran između vodika, metila i cijano.
40. Spoj prema zahtjevu 40, naznačen time što je R5 vodik ili metil.
41. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što su R2 i R3 nezavisno jedan od drugoga izabrani između vodika, C1-4 hidrokarbil i C1-4 acil
42. Spoj prema zahtjevu 42, naznačen time što su R2 i R3 nezavisno jedan od drugoga izabrani između vodika i metila.
43. Spoj prema zahtjevu 43, naznačen time što su oba R2i R3 vodik.
44. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što ima molekulsku težinu manju od 525.
45. Spoj prema zahtjevu 1 formule (I), naznačen time što je: 2-fenil-2-[4-(1H-pirazol-4-il)-fenil]-etilamin; 3-fenil-2-[3-(1H-pirazol-4-il)-fenil]-propionitril; 2-[4-(3,5-dimetil-1H-pirazol-4-il)-fenil]-2-fenil-etilamin; 2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etilamin; 2-[3-(3,5-dimetil-1H-pirazol-4-il)-fenil]-1-fenil-etilamin; 3-fenil-2-[3-(1H-pirazol-4-il)-fenil]-propilamin; 3-fenil-2-[4-(1H-pirazol-4-il)-fenil]-propilamin; {3-(4-kloro-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propil}-metil-amin; {3-(3,4-difluoro-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propil}-metil-amin; {3-(3-kloro-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propil}-metil-amin; 3-(4-kloro-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propionamid; 3-(4-kloro-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propilamin; 3-(3,4-dikloro-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propilamin; 4-(4-kloro-fenil)-4-[4-(1H-pirazol-4-il)-fenil]-piperidin; 4-(4-metoksi-fenil)-4-[4-(1H-pirazol-4-il)-fenil]-piperidin; 4-(4-kloro-fenil)-1-metil-4-[4-(1H-pirazol-4-il)-fenil]-piperidin; 4-fenil-4-[4-(1H-pirazol-4-il)-fenil]-piperidin; 4-[4-(3,5-dimetil-1H-pirazol-4-il)-fenil]-4-fenil-piperidin; dimetil-{3-[4-(1H-pirazol-4-il)-fenil]-3-piridin-2-il-propil}-amin; {2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-dimetil-amin; {2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-metil-amin; {2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-metil-amin (R); {2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-metil-amin (S); 4-{2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-morfolin; 4-{4-[1-(4-kloro-fenil)-2-pirolidin-1-il-etil]-fenil}-1H-pirazol; {2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-izopropil-amin; dimetil-{2-fenil-2-[4-(1H-pirazol-4-il)-fenil]-etil}-amin; {2,2-bis-[4-(1H-pirazol-4-il)-fenil]-etil}-dimetil-amin; {2,2-bis-[4-(1H-pirazol-4-il)-fenil]-etil}-metil-amin; 2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etilamin (R); 2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etilamin (S); 2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-acetamid; 1-{2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-piperazin; 1-{2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-piperidin; 4-{4-[2-azetidin-1-il-1-(4-kloro-fenil)-etil]-fenil}-1H-pirazol; 1-fenil-2-[4-(1H-pirazol-4-il)-fenil]-etilamin; 2-(4-kloro-fenil)-N-metil-2-[4-(1H-pirazol-4-il)-fenil]-acetamid; N-metil-2,2-bis-[4-(1H-pirazol-4-il)-fenil]-acetamid; {2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-metil-amin; {2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-etil-amin; 4-{4-[1-(4-kloro-fenil)-2-imidazol-1-il-etil]-fenil}-1H-pirazol; metil-{2-(4-fenoksi-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-amin; {2-(4-metoksi-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-metil-amin; metil-{2-[4-(pirazin-2-iloksi)-fenil]-2-[4-(1H-pirazol-4-il)-fenil]-etil}-amin; metil-{2-fenoksi-2-[4-(1H-pirazol-4-il)-fenil]-etil}-amin; 2-{(4-kloro-fenil)-[4-(1H-pirazol-4-il)-fenil]-metoksi}-etilamin; 4-{4-[1-(4-kloro-fenil)-3-pirolidin-1-il-propil]-fenil}-1H-pirazol; 4-{4-[3-azetidin-1-il-1-(4-kloro-fenil)-propil]-fenil}-1H-pirazol; metil-{3-naftalen-2-il-3-[4-(1H-pirazol-4-il)-fenil]-propil}-amin; {3-(4-fluoro-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propil}-metil-amin; 4-{4-[4-(4-kloro-fenil)-piperidin-4-il]-fenil}-1H-pirazol-3-karbonitril; 3-(4-fenoksi-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propilamin; 1-{(4-kloro-fenil)-[4-(1H-pirazol-4-il)-fenil]-metil}-piperazin; 1-metil-4-{fenil-[4-(1H-pirazol-4-il)-fenil]-metil}-[1,4]diazepan; {3-(3-kloro-fenoksi)-3-[4-(1H-pirazol-4-il)-fenil]-propil}-metil-amin; metil-{2-fenil-2-[6-(1H-pirazol-4-il)-piridin-3-il]-etil}-amin; 4-{4-[1-(4-kloro-fenil)-3-imidazol-1-il-propil]-fenil}-1H-pirazol; 4-[4-(3-imidazol-1-il-1-fenoksi-propil)-fenil]-1H-pirazol; 4-{4-[4-(1H-pirazol-4-il)-fenil]-piperidin-4-il}-fenol; 1-{(4-kloro-fenil)-[4-(1H-pirazol-4-il)-fenil]-metil}-piperazin; {2-(4-fluoro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-metil-amin; {2-(3-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-metil-amin; 4-[4-(2-metoksi-etoksi)-fenil]-4-[4-(1H-pirazol-4-il)-fenil]-piperidin; 4-[4-(3-metoksi-propoksi)-fenil]-4-[4-(1H-pirazol-4-il)-fenil]-piperidin; 3-(3,4-dikloro-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propionamid; 2-(4-{2-metilamino-1-[4-(1H-pirazol-4-il)-fenil]-etil}-fenoksi)-izonikotinamid; {2-(3-kloro-fenoksi)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-metil-amin; 3-{2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etilamino}-propan-1-ol; 2-{2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etilamino}-etanol; 3-{2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etilamino}-propan-1-ol; 2-{2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etilamino}-etanol; {2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-ciklopropilmetil-amin; metil-[2-[4-(1H-pirazol-4-il)-fenil]-2-(4-piridin-3-il-fenil)-etil]-amin; 4-{3-metilamino-1-[4-(1H-pirazol-4-il)-fenil]-propil}-fenol; 3-(4-metoksi-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propilamin; 4-(4-kloro-fenil)-4-[4-(3-metil-1H-pirazol-4-il)-fenil]-piperidin; 2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-morfolin; (4-{4-[4-(1H-pirazol-4-il)-fenil]-piperidin-4-il}-fenoksi)-octena kiselina; 4-{4-[4-(1H-pirazol-4-il)-fenil]-piperidin-4-il}-benzonitril; {2-(4-kloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-propil}-metil-amin; 1-(4-kloro-fenil)-2-metilamino-1-[4-(1H-pirazol-4-il)-fenil]-etanol; 2-amino-1-(4-kloro-fenil)-1-[4-(1H-pirazol-4-il)-fenil]-etanol; 4-(3,4-dikloro-fenil)-4-[4-(1H-pirazol-4-il)-fenil]-piperidin; 4-(3-kloro-4-metoksi-fenil)-4-[4-(1H-pirazol-4-il)-fenil]-piperidin; 4-(4-kloro-3-fluoro-fenil)-4-[4-(1H-pirazol-4-il)-fenil]-piperidin; 4-[4-(1H-pirazol-4-il)-fenil]-1,2,3,4,5,6-hexahidro-[4,4']bipiridinil; 3-(3-kloro-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propilamin; 2-metilamino-1-(4-nitro-fenil)-1-[4-(1H-pirazol-4-il)-fenil]-etanol; 2-(3-kloro-4-metoksi-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etilamin; 2-(4-kloro-fenil)-2-fluoro-2-[4-(1H-pirazol-4-il)-fenil]-etilamin; 3-(3,4-dikloro-fenil)-3-[6-(1H-pirazol-4-il)-piridin-3-il]-propilamin; 2-(4-kloro-3-fluoro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etilamin; 4-(2-kloro-3-fluoro-fenil)-4-[4-(1H-pirazol-4-il)-fenil]-piperidin; 1-{(3,4-dikloro-fenil)-[4-(1H-pirazol-4-il)-fenil]-metil}-piperazin; 2-(3,4-dikloro-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etilamin; {2-(3-kloro-4-metoksi-fenil)-2-[4-(1H-pirazol-4-il)-fenil]-etil}-metil-amin; 4-{4-[2-azetidin-1-il-1-(4-kloro-fenoksi)-etil]-fenil}-1H-pirazol; 3-(3-kloro-4-metoksi-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propilamin; {3-(3-kloro-4-metoksi-fenil)-3-[4-(1H-pirazol-4-il)-fenil]-propil}-metil-amin; 1-{(3,4-dikloro-fenil)-[4-(1H-pirazol-4-il)-fenil]-metil}-piperazin; ili C-(4-kloro-fenil)-C-[4-(1H-pirazol-4-il)-fenil]-metilamin; i njihove soli, solvati, tautomeri i N-oksidi.
46. Spoj prema zahtjevu 46, naznačen time što je 2-amino-1-(4-kloro-fenil)-1-[4-(1H-pirazol-4-il)-fenil]-etanol ili njegova sol, solvat, tautomer ili N-oksid.
47. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što je u obliku soli, solvata, estera ili N-oksida.
48. Spoj kako je definiran u bilo kojem od zahtjeva 1 do 48, naznačen time što se koristi u medicini.
49. Spoj kako je definiran u bilo kojem od zahtjeva 1 do 48, naznačen time što se koristi za (a) prevenciju ili liječenje bolesti ili stanja posredovanog protein kinazom B; ili (b) za prevenciju ili liječenje bolesti ili stanja posredovanog protein kinazom A.
50. Spoj kako je definiran u bilo kojem od zahtjeva 1 do 48, naznačen time što se koristi za prevenciju ili liječenje bolesti ili stanja izabranih iz skupine karcinoma mjehura, dojke, kolona, bubrega, epiderme, jetre, pluća, jednjaka, žučnog mjehura, jajnika, gušterače, želuca, grlića maternice, endometrija, štitnjače, prostate ili kože, hematopoetskih tumora limfoidne linije, hematopoetskih tumora mijeloične linije, folikularnog karcinoma štitnjače, tumora mezenhimskog porijekla, tumora središnjeg ili perifernog živčanog sustava, melanoma, seminoma, teratokarcinoma, osteosarkoma, xeroderma pigmentosum, keratoksantoma, folikularnog karcinoma štitnjače ili Kaposijevog sarkoma.
51. Spoj kako je definiran u bilo kojem od zahtjeva 1 do 48, naznačen time što se koristi za prevenciju ili liječenje bolesti ili stanja izabranih iz skupine raka dojke, raka jajnika, raka kolona, raka prostate, raka jednjaka, skvamoznog karcinoma i karcinoma ne-malih stanica pluća.
52. Uporaba spoja kako je definiran u bilo kojem od zahtjeva 1 do 48, naznačena time što se radi o uporabi za: (a) proizvodnju lijeka za prevenciju ili liječenje bolesti ili stanja posredovanog protein kinazom B; ili (b) proizvodnju lijeka za prevenciju ili liječenje bolesti ili stanja posredovanog protein kinazom A; ili (c) proizvodnju lijeka za prevenciju ili liječenje bolesti ili stanja koje proizlazi iz abnormalnog rasta stanica; (d) proizvodnju lijeka za prevenciju ili liječenje bolesti kod koje postoji poremećaj proliferacije, apoptoze ili diferencijacije.
53. Farmaceutska smjesa, naznačena time što sadrži novi spoj kako je definiran u bilo kojem od zahtjeva 1 do 48 i farmaceutski prihvatljiv nosač.
54. Postupak pripreme spoja formule (I) kako je definiran u bilo kojem od zahtjeva 1 do 48, naznačen time što obuhvaća: (a) reakciju spoja formule (X) sa spojem formule (XI) ili njegovim N-zaštićenim derivatom: [image] u prisutnosti paladijevog katalizatora i baze, gdje su A, E, i R1 do R5 kako su definirani u bilo kojem od zahtjeva 1 do 48, jedna od skupina X i Y je izabrana između klora, broma, joda i trifluorometansulfonata, a druga od skupina X i Y je boronat ester ili ostatak boronske kiseline; (b) reduktivnu aminaciju spoja formule (XXXVI): [image] (XXXVI) s HNR2R3 u prisutnosti reducensa; i po izboru (c) pretvorbu jednog spoja formule (I) u drugi spoj formule (I).
HR20100675T 2003-12-23 2010-12-07 Derivati pirazola kao modulatori protein kinaze HRP20100675T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53219903P 2003-12-23 2003-12-23
GB0329617A GB0329617D0 (en) 2003-12-23 2003-12-23 Pharmaceutical compounds
US57784304P 2004-06-08 2004-06-08
PCT/GB2004/005464 WO2005061463A1 (en) 2003-12-23 2004-12-23 Pyrazole derivatives as protein kinase modulators

Publications (1)

Publication Number Publication Date
HRP20100675T1 true HRP20100675T1 (hr) 2011-01-31

Family

ID=34714054

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100675T HRP20100675T1 (hr) 2003-12-23 2010-12-07 Derivati pirazola kao modulatori protein kinaze

Country Status (17)

Country Link
US (4) US8247576B2 (hr)
EP (2) EP2228369A1 (hr)
JP (1) JP4928949B2 (hr)
KR (1) KR101164258B1 (hr)
AU (1) AU2004303602C1 (hr)
BR (1) BRPI0418078A8 (hr)
CA (1) CA2548374C (hr)
CY (1) CY1111493T1 (hr)
HK (1) HK1097543A1 (hr)
HR (1) HRP20100675T1 (hr)
IL (1) IL176400A (hr)
MX (1) MXPA06007326A (hr)
NO (1) NO20062633L (hr)
NZ (1) NZ547696A (hr)
PL (1) PL1706385T3 (hr)
UY (1) UY28946A1 (hr)
WO (1) WO2005061463A1 (hr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003201273A1 (en) 2002-01-04 2003-07-30 Poseidon Pharmaceuticals A/S Potassium channel modulators
NZ547696A (en) 2003-12-23 2009-12-24 Astex Therapeutics Ltd Pyrazole derivatives as protein kinase modulators
UY29610A1 (es) * 2005-06-21 2007-01-31 Cancer Rec Tech Ltd Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
GB2427406A (en) * 2005-06-21 2006-12-27 Astex Technology Ltd Silicon-containing PKB/PKA kinase inhibitors
WO2006136829A2 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Pyrazole derivatives and their use as pka and pkb modulators
WO2006136823A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
WO2006136821A1 (en) * 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
WO2006136837A2 (en) * 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
SI3184526T1 (sl) 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
GB0704932D0 (en) * 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
PL2173752T5 (pl) 2007-06-13 2022-12-05 Incyte Holdings Corporation Sole (r)-3-(4-(7h-pirolo(2,3-d)pirymidyn-4-ylo)-1h-pirazol-1-ilo)-3-cyklopentylopropanonitrylu inhibitora kinazy janusowej
US8334308B2 (en) * 2007-08-20 2012-12-18 Merck Sharp & Dohme Corp. Renin inhibitors
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX2011012262A (es) 2009-05-22 2012-01-25 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
DK2574168T3 (en) 2010-05-21 2016-05-09 Incyte Holdings Corp Topical formulation to a jak inhibitor
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
MX2015011667A (es) 2013-03-06 2015-12-16 Incyte Corp Procesos e intermedios para hacer un inhibidor de jak.
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
MX2016012368A (es) 2014-03-26 2017-02-23 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
KR102479693B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 조합물
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
MA41350A (fr) * 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
SI3353177T1 (sl) 2015-09-23 2020-08-31 Janssen Pharmaceutica Nv Triciklični heterocikli za zdravljenje raka
WO2017050865A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
EP3877511A1 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
CN110372530B (zh) * 2019-08-06 2021-07-30 郑州大学 一种含α取代苯基结构的化合物及其制备方法和消杀剂
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2438106A (en) * 1944-06-09 1948-03-23 Wyeth Corp Peroral penicillin compositions
US2645594A (en) * 1948-10-19 1953-07-14 Abbott Lab Antiseptic acridane compounds
US2596069A (en) * 1952-03-07 1952-05-06 Hoffmann La Roche Compositions for combating tuberculosis
US2736681A (en) * 1955-02-11 1956-02-28 Merck & Co Inc Chemical compounds
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IE900394L (en) 1989-02-08 1990-08-08 Abbott Lab Thiazole derivatives
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5049570A (en) 1990-01-23 1991-09-17 Du Pont Merck Pharmaceutical Company Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5532356A (en) * 1995-06-06 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N,N'-disubstituted cyclic ureas
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
AU721952B2 (en) 1996-04-03 2000-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB2339298B (en) * 1996-04-30 2000-05-10 Eastman Kodak Co Use of pyrazolone image dye-forming couplers for enhancing light stability
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
GB9700555D0 (en) * 1997-01-13 1997-03-05 Merck Sharp & Dohme Therapeutic agents
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
EP1051169A4 (en) 1998-01-29 2002-05-29 Viropharma Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRAL INFECTIONS AND RELATED DISEASES
GB9804734D0 (en) * 1998-03-05 1998-04-29 Pfizer Ltd Compounds
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
US6503905B1 (en) 1998-12-29 2003-01-07 Pfizer Inc 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
WO2000066562A1 (en) 1999-05-03 2000-11-09 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
NZ515460A (en) 1999-05-14 2004-06-25 Neurocrine Biosciences Inc Imidazo- and pyrrolo[1,2-A]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
BRPI0014076B8 (pt) 1999-09-17 2021-05-25 Millennium Pharm Inc benzamidas e inibidores correlatos do fator xa
HUP0203954A2 (hu) 1999-09-17 2003-03-28 Millennium Pharmaceuticals, Inc. Xa faktor inhibitorok
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
IL152807A0 (en) 2000-05-30 2003-06-24 Peptor Ltd Protein kinase inhibitors
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
ATE402164T1 (de) 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
AU2002305260A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
DE60226154T2 (de) 2001-08-03 2009-05-20 Vertex Pharmaceuticals Inc., Cambridge Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
FR2830192B1 (fr) 2001-09-28 2004-08-20 Oreal Composition tinctoriale comprenant une base d'oxydation du type diaminopyrazole et un coupleur pyrazolo-azole
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
PL218749B1 (pl) 2002-02-14 2015-01-30 Pharmacia Corp Pochodna pirydynonu oraz jej zastosowanie do wytwarzania leku
BR0308537A (pt) 2002-03-20 2005-02-09 Metabolex Inc Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga
EP3042630A1 (en) 2002-04-08 2016-07-13 Boston Scientific Scimed, Inc. Satiation devices and methods
WO2003090680A2 (en) 2002-04-23 2003-11-06 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
ATE547416T1 (de) 2002-07-24 2012-03-15 Dermira Canada Inc Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel
US7164021B2 (en) 2002-09-18 2007-01-16 The Curators Of The University Of Missouri Opiate analogs selective for the δ-opioid receptor
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
CA2530389A1 (en) 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
NZ547696A (en) 2003-12-23 2009-12-24 Astex Therapeutics Ltd Pyrazole derivatives as protein kinase modulators
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
UY29610A1 (es) 2005-06-21 2007-01-31 Cancer Rec Tech Ltd Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
GB2427406A (en) 2005-06-21 2006-12-27 Astex Technology Ltd Silicon-containing PKB/PKA kinase inhibitors
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
WO2006136829A2 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Pyrazole derivatives and their use as pka and pkb modulators
WO2006136821A1 (en) 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
WO2006136837A2 (en) 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
IL176400A (en) 2011-10-31
WO2005061463A1 (en) 2005-07-07
KR20060130621A (ko) 2006-12-19
HK1097543A1 (en) 2007-06-29
US9283226B2 (en) 2016-03-15
AU2004303602C1 (en) 2009-05-28
EP1706385B1 (en) 2010-10-06
US20160250187A1 (en) 2016-09-01
JP2007516272A (ja) 2007-06-21
US8247576B2 (en) 2012-08-21
NO20062633L (no) 2006-07-20
UY28946A1 (es) 2006-01-31
CY1111493T1 (el) 2015-08-05
US20110144080A1 (en) 2011-06-16
EP1706385A1 (en) 2006-10-04
BRPI0418078A (pt) 2007-04-17
BRPI0418078A8 (pt) 2018-01-02
EP2228369A1 (en) 2010-09-15
MXPA06007326A (es) 2007-01-26
CA2548374A1 (en) 2005-07-07
US20140271662A1 (en) 2014-09-18
US20130005702A1 (en) 2013-01-03
NZ547696A (en) 2009-12-24
KR101164258B1 (ko) 2012-07-11
PL1706385T3 (pl) 2011-03-31
US8691806B2 (en) 2014-04-08
JP4928949B2 (ja) 2012-05-09
IL176400A0 (en) 2006-10-05
AU2004303602B2 (en) 2008-12-18
AU2004303602A1 (en) 2005-07-07
CA2548374C (en) 2014-05-27

Similar Documents

Publication Publication Date Title
HRP20100675T1 (hr) Derivati pirazola kao modulatori protein kinaze
JP2007516272A5 (hr)
US8343953B2 (en) Pharmaceutical compounds
US9187465B2 (en) Oxazole tyrosine kinase inhibitors
TW502019B (en) Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
JP2008546751A5 (hr)
Akhtar et al. Recent progress of benzimidazole hybrids for anticancer potential
JP2020503299A5 (hr)
US20100210617A1 (en) Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors
EA021421B1 (ru) Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы, способ их получения, содержащая их фармацевтическая композиция и способ лечения заболеваний с применением таких соединений
JP2008546753A5 (hr)
NZ593594A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2013507351A5 (hr)
NZ591427A (en) P38 map kinase inhibitors
JP2008546754A5 (hr)
HRP20110759T1 (hr) Novi derivati imidazolona, njihovo dobivanje u svojstvu lijekova, njihovi farmaceutski pripravci i njihova upotreba u svojstvu inhibitora protein-kinaza, osobito cdc7
JP2004262890A (ja) ２０−ｈｅｔｅ産生阻害作用を有するアゾール誘導体
US20130090342A1 (en) Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
RU2419612C2 (ru) Производные пиразола в качестве модуляторов протеинкиназы
JPWO2019038387A5 (hr)
RU2020110504A (ru) Пиридилпиридоны
SA05260179B1 (ar) مركبات اريل الكيل امين واريل غير متجانس الكيل امين تحتوي على بيرازول تثبط أو تعدل من نشاط الكيناز البروتيني a (pks) والكيناز البروتيني b (pkb)